CA-HAI-SOLUTIONS
22.5.2023 12:01:33 CEST | Business Wire | Press release
Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access. The partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component in HAI Solutions' QIKcap™ technology to offer visible and verifiable IV port protection and provide confidence that the needle-free connector has been disinfected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005235/en/
The QIKcap (TM) disposable IV luer access cap with Intellego’s chromatic ink changes from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered by HAI Solutions QIKcap (TM) handheld UV-C disinfection device. (Photo: Business Wire)
The QIKcap Disinfection Device™ is a patented, handheld UV-C tool that is designed to irradiate the surface of an intravenous connector and intravenous access points to prevent microbial ingress. The specialized luer cap, known as QIKcap™, incorporates Intellego’s proprietary ink. When the QIKcap is irradiated with the UV-C handheld device, the cap changes color from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered in as little as one second.
The development of the QIKcap Disinfection Device and QIKcap is designed to address the continued risk of bloodstream infections (BSI) and hospital onset bacteremia (HOB), which is any positive blood culture obtained 48 hours after admission. In the 2023 Hospital Safety Grade data that was released on May 3, 2023 by The Leapfrog Group, healthcare-associated infections (HAIs) spiked to a 5-year high in U.S. hospitals during the COVID-19 pandemic and remain high. The report noted that the average CLABSI standard infection ratio increased by 60%. HAIs including Methicillin-resistant Staphylococcus aureus (MRSA), central line bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI) increase the length of hospitalization stays, add to costs and are the leading causes of death in the U.S.
This novel use of Intellego’s photochromic ink as an ingredient in a medical device is a first for the Swedish company that is best known for its product line, UVC Dosimeters. Used by OEMs, in academic research and in healthcare facilities around the world, UVC Dosimeters are the most trusted and reliable single-use UV indicators cards that provide visible measurement of germicidal ultraviolet energy delivered to surfaces.
According to Claes Lindahl, CEO of Intellego Technologies, “We are excited about the opportunity to expand the application of our proprietary ink technology in new and innovative ways to provide visible evidence of successful UV irradiation. Our partnership with HAI Solutions demonstrates our commitment to life-saving technologies and promoting the safety, efficacy and efficiency of ultraviolet disinfection applications.”
"We are thrilled to announce our new strategic partnership with Intellego Technologies,” said Nicholas Perrenoud, CEO of HAI Solutions. “By working together, we will be able to leverage our respective resources and capabilities to drive innovation, create new opportunities, and deliver even greater value to our stakeholders. We look forward to a successful and mutually beneficial partnership with Intellego."
About Intellego Technologies
Intellego Technologies is a research and development company, headquartered in Solna, Sweden. Founded in 2011, Intellego has grown to become the global leader in colorimetric indicators that are utilized worldwide to visually validate the dose of ultraviolet irradiation delivered to surfaces. Through its patented photochromic ink technology, Intellego manufactures standard and customized indicators that make the benefits of germicidal ultraviolet light visible and promotes the safe, effective and efficient use of UV applications. Intellego’s products support better outcomes with ultraviolet devices in healthcare, food and beverage manufacturing, environmental services, and more. For more information, visit Intellego-Technologies.com and UVCdosimeters.com.
About HAI Solutions
Based in Santa Barbara, CA, HAI Solutions is developing a novel and diverse platform of innovative intravenous therapy solutions targeting IV contamination which occurs in challenging medical segments like the Operating Room, Intensive Care Unit and Emergency Room. Founded in 2015, HAI Solutions believes in protecting every patient by advancing clinical care across the healthcare spectrum. For more information, please visit www.HAI-Solutions.com or Twitter @HAISolutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom